Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Otsuka Holdings Co., Ltd.
  6. Summary
    4578   JP3188220002

OTSUKA HOLDINGS CO., LTD.

(4578)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
4506 4487 4471 4461 4338 Last
571300 467500 408600 665500 663600 Volume
+0.92% -0.42% -0.36% -0.22% -2.76% Change
Estimated financial data (e)
Sales 2021 1 428 B 13 015 M 13 015 M
Net income 2021 149 B 1 362 M 1 362 M
Net cash position 2021 282 B 2 569 M 2 569 M
P/E ratio 2021 15,6x
Yield 2021 2,32%
Sales 2022 1 470 B 13 400 M 13 400 M
Net income 2022 151 B 1 380 M 1 380 M
Net cash position 2022 349 B 3 182 M 3 182 M
P/E ratio 2022 15,3x
Yield 2022 2,38%
Capitalization 2 353 B 21 435 M 21 447 M
EV / Sales 2021 1,45x
EV / Sales 2022 1,36x
Nbr of Employees 33 151
Free-Float 76,3%
More Financials
Company
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (64.4% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale... 
Sector
Pharmaceuticals
Calendar
08/06Earnings Release
More about the company
Ratings of Otsuka Holdings Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about OTSUKA HOLDINGS CO., LTD.
07/23MERIDIAN BIOSCIENCE : to Acquire Otsuka's North American BreathTek Business for ..
MT
07/08NIKKEI 225 : Declines 0.9% on Pandemic, Federal Reserve Outlooks
MT
07/01Dry Eye Syndrome Market 2026|Industry Analysis with Top Manufacturers- Allerg..
AQ
06/30UNICHEM LABORATORIES : Gets Tentative Approval from US FDA for Aripiprazole Tabl..
MT
06/29OTSUKA HOLDINGS CO., LTD. : Ex-dividend day for interim dividend
FA
06/25AURINIA PHARMACEUTICALS : Dual Listed Aurinia Licensing Partner Otsuka Files Ini..
MT
06/25AURINIA PHARMACEUTICALS' : Licensing Partner Files for Marketing Authorization f..
MT
06/23TEVA PHARMACEUTICAL INDUSTRIES : Secures Japanese Approval for Ajovy Injection a..
MT
06/09OTSUKA : Complete Introduction of CO2-free Electricity for All 23 Manufacturing ..
AQ
06/09Japanese electronics retailer Yamada to fully acquire furniture shop Otsuka K..
RE
06/08OTSUKA : Complete Introduction of CO2-free Electricity for All 23 Manufacturing ..
PU
06/02Decibel Therapeutics Names New Board Chairman
MT
06/01Akebia, Otsuka Say FDA Accepts New Drug Application for Anemia Drug Vadadusta..
MT
06/01OTSUKA : and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Applicat..
PU
05/14Otsuka Holdings Co., Ltd. Reports Consolidated Earnings Results for the First..
CI
More news
News in other languages on OTSUKA HOLDINGS CO., LTD.
07/27Tokyo est restée optimiste avant la saison des résultats
07/26Tokyo optimiste avant la saison des résultats
05/04IRW-PRESS : Sernova Corp. : Sernova gibt die Berufung der erfahrenen Pharma-Führ..
04/21IRW-PRESS : PsyBio Therapeutics Corp.: PsyBio Therapeutics beruft erfahrene phar..
04/13H. LUNDBECK A/S : coup d'arrêt
More news
Chart OTSUKA HOLDINGS CO., LTD.
Duration : Period :
Otsuka Holdings Co., Ltd. Technical Analysis Chart | 4578 | JP3188220002 | MarketScreener
Technical analysis trends OTSUKA HOLDINGS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Last Close Price 4 338,00 JPY
Average target price 4 654,17 JPY
Spread / Average Target 7,29%
EPS Revisions
Managers and Directors
Tatsuo Higuchi President, CEO & Representative Director
Yuko Makino Chief Financial Officer & Director
Ichiro Otsuka Chairman
Yukitakeshi Matsutani Independent Outside Director
Yasushi Sekiguchi Independent Outside Director